Table 1.
Summary of Some siRNA Targets in CRLM Treatment
| Target | Notes | References |
|---|---|---|
| PI3K-AKT-mTOR pathway | ||
| AKT | siRNA targeting AKT gene induces apoptosis | 27 |
| RAS-ERK pathway | ||
| RAGE | siRNA targeting against RAGE inhibits cancer cell stemness and development | 28 |
| Wnt/β-catenin pathway | ||
| CTNNB1 | siRNA against CTNNB1 significantly inhibits tumor growth | 29 |
| Bag-1 | Inhibition of overexpressed Bag-1 in colon cancer leads to the increase of apoptosis | 30 |
| NF-κB pathway | ||
| MUC13 | MUC13-specific siRNA reduces the cancer stem cells and lowers the resistance to therapy | 31 |
| IL-8 | Silencing of IL-8 expression through modulation of MDR1 leads to sensitizing of CRC cells to doxorubicin | 32 |
| Rac1 | Rac1 knockdown by siRNA causes suppression of migration and sensitization of colon cancer cells to dihydroartemisinin-induced cell cycle arrest | 33 |
| TGFβ/SMAD pathway | ||
| TGF-β1 | Downregulation of TGF-β1 decreases the volume and number of CRC metastatic foci and suppresses CRLM in vivo by optimization of the immune microenvironment | 22 |
| PAR2 | Application of siRNA against PAR2 inhibits the migration and EMT | 34 |
| MEGF6 | siRNA against MEGF6 suppresses the EMT | 35 |
| Combined targeting | ||
| PIK3CA and KRAS | Targeted delivery of siRNA against PIK3CA and KRAS inhibits the growth of human CRC xenograft tumor | 36 |
| Arl4c | Arl4c silencing by using specific siRNAs reduces the tumor growth in vivo | 37 |